| Potential treatment with Chinese and Western medicine targeting NSP14 of SARS-CoV-2 C Liu, X Zhu, Y Lu, X Zhang, X Jia, T Yang Journal of pharmaceutical analysis 11 (3), 272-277, 2021 | 46 | 2021 |
| Associate toxin-antitoxin with CRISPR-Cas to kill multidrug-resistant pathogens R Wang, X Shu, H Zhao, Q Xue, C Liu, A Wu, F Cheng, L Wang, Y Zhang, ... Nature Communications 14 (1), 2078, 2023 | 20 | 2023 |
| Divergent degeneration of creA antitoxin genes from minimal CRISPRs and the convergent strategy of tRNA-sequestering CreT toxins F Cheng, R Wang, H Yu, C Liu, J Yang, H Xiang, M Li Nucleic Acids Research 49 (18), 10677-10688, 2021 | 12 | 2021 |
| The toxin–antitoxin RNA guards of CRISPR-Cas evolved high specificity through repeat degeneration F Cheng, A Wu, C Liu, X Cao, R Wang, X Shu, L Wang, Y Zhang, H Xiang, ... Nucleic Acids Research 50 (16), 9442-9452, 2022 | 8 | 2022 |
| Widespread RNA-based cas regulation monitors crRNA abundance and anti-CRISPR proteins C Liu, R Wang, J Li, F Cheng, X Shu, H Zhao, Q Xue, H Yu, A Wu, L Wang, ... Cell Host & Microbe 31 (9), 1481-1493. e6, 2023 | 7 | 2023 |
| CRISPR-repressed toxin–antitoxin provides herd immunity against anti-CRISPR elements X Shu, R Wang, Z Li, Q Xue, J Wang, J Liu, F Cheng, C Liu, H Zhao, C Hu, ... Nature Chemical Biology, 1-11, 2024 | 2 | 2024 |
